Vividion Therapeutics Acquires Tavros Therapeutics

January 12, 2025

Vividion Therapeutics, a wholly owned subsidiary of Bayer AG, has acquired precision oncology platform company Tavros Therapeutics. The acquisition expands Vividion’s functional genomics and genomic screening capabilities, combining Tavros’s platform with Vividion’s chemoproteomics expertise to accelerate discovery of novel targets in oncology and immunology; financial terms were not disclosed.

Buyers
Vividion Therapeutics
Targets
Tavros Therapeutics
Industry
Biotechnology
Location
North Carolina, United States
Transaction Type
Buyout

Explore More

Related articles

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.

Find buyers like these →